Search

Your search keyword '"tafamidis"' showing total 966 results

Search Constraints

Start Over You searched for: Descriptor "tafamidis" Remove constraint Descriptor: "tafamidis"
966 results on '"tafamidis"'

Search Results

1. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis.

2. Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications.

Catalog

Books, media, physical & digital resources

3. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics.

4. RESHAPING TREATMENT PARADIGMS: Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry's pipeline remains flush with many late-stage therapies showing promising data and transformative potential

5. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan

6. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy

7. Right ventricular myocardial biopsy with a guiding catheter for conduction system pacing during pacemaker implantation revealed transthyretin cardiac amyloidosis

8. Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis

9. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.

10. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.

11. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.

12. Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience.

13. Effect of Timely Availability of TTR-Stabilizing Therapy on Diagnosis, Therapy, and Clinical Outcomes in ATTR-CM.

14. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy.

15. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin‐mediated amyloidosis with polyneuropathy.

16. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.

17. Safety, Tolerability, and Outcomes of Tafamidis for the Treatment of Acquired Amyloid Neuropathy in Domino Liver Transplant Recipients.

18. Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment.

19. Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis.

20. Myocardial work assessment to improve baseline risk stratification in patients with transthyretin amyloidosis

21. No body fits in the test tube – the case of transthyretin.

24. Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence

25. Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

26. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study

27. Safety, Tolerability, and Outcomes of Tafamidis for the Treatment of Acquired Amyloid Neuropathy in Domino Liver Transplant Recipients

28. Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence.

29. Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system.

30. Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).

31. Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy.

32. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study.

34. Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)

35. Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

36. A clinical case of transthyretin amyloidosis with manifestations of seronegative arthritis

37. Experience with tafamidis in peritoneal dialysis for a patient diagnosed with transthyretin cardiac amyloidosis.

38. Chest pain in a patient with transthyretin cardiac amyloidosis: A case report.

39. Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy.

40. Reduction in 99mTc-DPD myocardial uptake with therapy of ATTR cardiomyopathy.

41. Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data

42. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy

43. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study

44. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy

45. Chest pain in a patient with transthyretin cardiac amyloidosis: A case report

46. Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment.

47. Tafamidis Drug Delivery Systems Based on Chitosan/Polyvinyl Alcohol Matrix †.

48. Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation.

49. Croatian Transthyretin Cardiac Amyloidosis Registry - an update.

50. A case of disappearing amyloid on technetium pyrophosphate scan.